Business Developer
The ideal candidate is a motivated, energetic, and creative individual who welcomes the challenges of acquiring and developing new business through partnering and sales efforts. You have Pharma experience and a proven network in BIGpharma (US and Europe). You will build strong partnerships and customer relationships, identify business opportunities, and close business deals while maintaining an extensive knowledge of current market conditions.
Responsibilities
Qualifications
Interested? Please send us your CV and motivation letter. Contact Iris Garnier for more information.
Recruiters should not contact us.
Clinical Trial Operations Manager
Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.
Catapult Therapeutics was established in 2015 as a joint venture between Spanish and Dutch partners. Catapult is founded on the discoveries of Dr Cecilia Munoz and her group at Hospital La Princesa in Madrid. They identified and validated CCR7 as a therapeutic target for leukemias and lymphomas. Technology of Dutch biotech company Pepscan made it possible to generate antibodies against human CCR7.
The chemokine receptor CCR7 is over-expressed in many cancers, and high CCR7 expression is associated with poor prognosis and short survival in hematological and solid malignancies. Preclinical studies have shown that the anti-CCR7 antibody can prolong survival and inhibit cancer cell migration in multiple animal models of B-cell and T-cell lymphomas.
CAP-100 has a uniquely differentiated mechanism of action, which is complementary to current standard of care treatments for hematological malignancies. Thus, CAP-100 is a potential monotherapy and can be used in combination with current standard treatments.
CAP-100 has completed preclinical development, with IND filing in December 2020. The preparations for the start of the first study in patients are ongoing.
The opportunity
Catapult Therapeutics is currently entering the clinical trial phase 1. To realize our ambition, we are looking for a hands-on clinical trial operations manager with proven knowledge of all aspects of clinical operations, preferably in oncology.
The basic responsibility is to deliver and execute the Catapult clinical development strategy for CAP-100 in a cost effective, safe and regulatory compliant fashion.
Proficiencies
The ideal candidate with life science background has a sound understanding of the pharmaceutical development process and has proven clinical trial experience. The candidate has a good understanding of stakeholder management, is accountable as project manager, and is thrilled by being in the frontline of breakthrough developments in cancer therapies. It’s a great advantage if the candidate has led the successful early clinical development of a new product.
Your responsibilities
Your education, skills and experiences
Your profile
What we offer
The position (32-40 h/week) offers an opportunity to work within a small team, with great autonomy and entrepreneurial, science-loving colleagues, all of whom are committed to improving the lives of patients.
Catapult Therapeutics’s offers an informal ambitious working environment. We offer a market conform salary and a good pension plan. The right candidate will be welcomed enthusiastically.
Interested? Please send us your CV and motivation letter. Contact Iris Garnier for more information.
Recruiters should not contact us.
CEO
Company introduction
Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.
Catapult Therapeutics was established in 2015 as a joint venture between Spanish and Dutch partners. Catapult is founded on the discoveries of Dr Cecilia Munoz and her group at Hospital La Princesa in Madrid. They identified and validated CCR7 as a therapeutic target for leukemias and lymphomas. Technology of Dutch biotech company Pepscan made it possible to generate antibodies against human CCR7.
The chemokine receptor CCR7 is over-expressed in many cancers, and high CCR7 expression is associated with poor prognosis and short survival in hematological and solid malignancies. Preclinical studies have shown that the anti-CCR7 antibody can prolong survival and inhibit cancer cell migration in multiple animal models of B-cell and T-cell lymphomas.
CAP-100 has a uniquely differentiated mechanism of action, which is complementary to current standard of care treatments for hematological malignancies. Thus, CAP-100 is a potential monotherapy and can be used in combination with current standard treatments.
CAP-100 has completed preclinical development, with IND filing in December 2020. The preparations for the start of the first study in patients are ongoing.
The opportunity
Catapult Therapeutics is currently entering the clinical trial phase 1. To realize our ambition, we are looking for a hands-on CEO with proven track record in international business development and partnering as well as operational experience in running clinical trials.
Proficiencies
The ideal candidate with life science background is entrepreneurial, is driven by growing the business to the optimum level for treatment of humans and is thrilled by being in the frontline of breakthrough developments in cancer therapies. The candidate has a good understanding of stakeholder management, he/ she is accountable as project manager, has an overview of the pharmaceutical industry, and has a sound understanding of the pharmaceutical development process and more specifically he/ she has clinical trial experience. It’s a great advantage if the candidate has led the successful early clinical development and partnering of a new product.
Your responsibilities
Your education/experience
Your profile
What we offer
The position offers an opportunity to work within a small team, with great autonomy and entrepreneurial, science-loving colleagues, all of whom are committed to improving the lives of patients.
Catapult Therapeutics’s offers an informal ambitious working environment. We offer a market conform salary and a good pension plan. The right candidate will be welcomed enthusiastically.
Interested? Please send us your CV and motivation letter. Contact Iris Garnier for more information.
Recruiters should not contact us.
Copyright 2019 @ Dulisco. All rights reserved.
Developed by Juist